Conditions: Colorectal Neoplasms
Keywords: K-RAS FcγRII/IIIa genotypes CRC Colorectal cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 73
Healthy volunteers: no

Brief summary:
This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa polymorphism tumors, in which there is no therapeutic alternative for treatment. Failure of the first and second line conventional therapeutic lines was documented.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Cetuximab
Intervention descriptions: intervention 1: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.

Protocol document: